Navigation Links
Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
Date:5/21/2008

TAMPA, Fla., May 21 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biopharmaceutical company, today announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in U.S. patients with chronic hepatitis C genotype 1 who have previously failed to respond to the standard of care therapy (peginterferon and ribavirin). The company expects to announce interim data results at a medical meeting this fall. Romark recently announced the initiation of a Phase II trial of nitazoxanide in treatment-naive patients with chronic hepatitis C infected with genotype 1 (STEALTH C-3).

"Completing enrollment in this Phase II trial is a significant achievement for Romark and an important step in the clinical development of nitazoxanide," stated Marc Ayers, Chief Executive Officer of Romark. "We believe nitazoxanide represents a promising approach to the treatment of hepatitis C for the millions of people who are infected with this serious liver disease."

The study, called STEALTH C-2 (Studies to Evaluate Alinia for Treatment of Hepatitis C), is the second in a series of clinical trials designed to evaluate the safety and efficacy of nitazoxanide tablets in combination with Pegasys(R) (peginterferon alfa-2a) or peginterferon and Copegus(R) (ribavirin) in patients with chronic hepatitis C. STEALTH C-2 is a randomized, double-blind, placebo-controlled trial conducted in the United States in 60 patients with chronic hepatitis C genotype 1, who are non-responders to prior peginterferon and ribavirin therapy. The study is designed to evaluate the effectiveness and safety of nitazoxanide administered 500 mg twice daily for four weeks followed by nitazoxanide plus Pegasys plus Copegus combination therapy for 48 weeks, compared to placebo for four weeks followed by placebo plus Pegasys plus Copegus combination therapy for 48 weeks. Pegasys and Copegus are be
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
2. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
3. Romark Laboratories Raises $18 Million in Institutional Financing
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
6. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
7. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
8. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
9. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
10. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...Pharmaceuticals (SPI) has filed,an Investigational...l,testing of a proprietary formulation of ebselen ... loss or ototoxicity. The oral capsule,containing ...e lung cancer,and head and neck cancer patients re...e second development program for SPI to enter clin...
(Date:7/23/2008)... Have Greater Concentrations of,Stem Cells, ARLIN.../ -- Fat removed,from the lower abdomen and inner ...lent source of stem cells, with higher stem cell c...s a Brazilian-based study in August,s,Plastic and ...urnal of the,American Society of Plastic Surgeons ...
(Date:7/23/2008)...th Protein Therapeutics that Modulate Al..., Mass., July 23 /- Taligen Therapeut...ate growth plan with the,appointment of Abbie Celn...tablishment of its headquarters in Cambridge, Mass...-founder of the company who remains president., U...
(Date:7/22/2008)...nin Medical, a leading innovator,of physiological ...ntered,the clinical testing phase with its breakth...tion. Today,s most common application for this,tec...al blood oxygenation,in the brain -- cerebral oxim...going clinical study at the,Duke University Medica...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 1Symmetry Medical Delays 10 K Filing to Complete Review 15357 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 3Symmetry Medical Delays 10 K Filing to Complete Review 15357 4Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 1Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 2Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 3Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 1Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 2Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 3Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 1Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 2
...Annual Meeting of the American,Psychiatric Associa...all/ -- In adults with,major depressive disorder, ...) resulted in significant improvement in the prima...ing Scale (MADRS),Total Score. In this six-week, r... at the 160th Annual Meeting of the American,Psych...
...ewswire/ -- Asenapine -- an,investigational drug b...siness unit of Akzo Nobel, for bipolar I disorder ...ffective than placebo,in treating acute manic and ... according to new Phase III results, from a study,...s 2007 Annual,Meeting. , In the three-week study, ...
Other Medicine Technology:Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4
(Date:7/25/2008)...er Releases Results of Fourth Annual Physician On-...DETROIT, July 25 /PRNewswire/ -- Sullivan, Cotter ...al survey of physician on-call pay rates and,pract.... The survey report,with data from 132 healthcare...all pay practices and rates paid for 33 physician ...
(Date:7/25/2008)...ionship Based on Significant Improvements in Membe...tacor, Inc., a leader in health,care quality manag...day,announced it has entered into a long-term agre...ellmark,s Collaboration on Quality(SM) Incent and,...between Wellmark and,primary care clinicians to pr...
(Date:7/25/2008)...ly 25 /PRNewswire/ -- The Elekta Family of Compani...ment solutions at the 2008,American Association of...onstrating how the joint forces of Elekta, IMPAC a...py planning and delivery solutions that,streamline...ce for,patients, as well as enhance clinician effi...
(Date:7/25/2008)...id back-up in esophagus can cause immune system ch...s) -- The first evidence linking gastroesophageal ...ed by Duke University Medical Center researchers. ... first noted in the 1970s, and since then studies ...of asthma patients also experience GERD symptoms. ...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2
...g rod of Chikungunya, the ruling Left Democratic... quest for a 'politically correct' low-cost health...Front (LDF) government had dumped its BPL (below p...CI Lombard to seek out a cost-competitive, quality...
... lymphoma became substantially more common in the ... a report in the July issue of Archives of Dermato...nd geographic area. Cutaneous T-cell lymphoma occ...tem (called T lymphocytes) become cancerous and af...
...t his 90 day stint at the Betty Ford clinic in Pal...to Nicole Kidman from collapsing . The singer ent... after the couple wed in June that year. Urban ho...tering rehab at the time was one of the wisest dec...
...ssage in one ear while a friend is talking into yo... an important communication skill thats heavily in...ional Institute on Deafness and Other Communicatio...l Institutes of Health. The finding, published in...
Other Medicine News:Health News:Kerala Government Battles With Chikungunya On All Counts 2Health News:Cutaneous T-cell Lymphoma Shows Steady Increase 2Health News:Genes Influence the Ability to Listen Two Things at a Time 2Health News:Genes Influence the Ability to Listen Two Things at a Time 3
The Sphincter of Oddi Manometry Application for POLYGRAM NET™ (PNET) works with the Polygraf™ ID multiparametric recorder to record and analyze pressure signals from sphincter of Oddi man
...rise the SmartPill GI Monitoring System., ,Three ...toring System: SmartPill pH.p Capsule software, Sm...iGI software. These three components are integrate...toring System and function together with system ha...
... NET™ (PNET) works with the Polygraf™ ...pressure signals from continuous pull-through proc...cter (LES)., ,Continuous pull-through procedures ...r Puller, but they may be carried out manually wit...
... POLYGRAM NET™ works with the Polygraf&trade...e multichannel EGG signals. The EGG analysis takes...ng an automatic electrode impedance check on every...ording. If the electrode impedance is measured abo...
Medicine Products: